Literature DB >> 33044375

Pain Control and Medication Use in Children Following Closed Reduction and Percutaneous Pinning of Supracondylar Humerus Fractures: Are We Still Overprescribing Opioids?

Matthew R Stillwagon1, Shawn Feinstein, Byrd Nichols, Paul N Andrews, Anna D Vergun.   

Abstract

BACKGROUND: The purpose of this 2-part study is to determine opioid prescribing patterns and characterize actual opioid use and postoperative pain control in children following discharge after closed reduction and percutaneous pinning of a supracondylar humerus fracture.
METHODS: A retrospective study was conducted from 2014 to 2016 to determine pain medication prescribing patterns at a single level 1 trauma center. Next, a prospective, observational study was conducted from 2017 to 2018 to determine actual pain medication use and pain scores in the acute postoperative period. Data were collected through telephone surveys performed on postoperative day 1, 3, and 5. Pain scores were collected using a parental proxy numerical rating scale (0 to 10) and opioid use was recorded as the number of doses taken.
RESULTS: From 2014 to 2016, there were 126 patients who were prescribed a mean of 47 doses of opioid medication at discharge. From 2017 to 2018, telephone questionnaires were completed in 63 patients. There was no significant difference (P>0.05) in pain ratings or opioid use by fracture type (Gartland), age, or sex. Children required a mean of 4 doses of oxycodone postoperatively. There were 18 (28%) patients who did not require any oxycodone. On average, pain scores were highest on postoperative day 1 (average 5/10) and decreased to clinically unimportant levels (<1) by postoperative day 5. Acetaminophen and ibuprofen were utilized as first-line pain medications in only 25% and 9% of patients, respectively. Two of 3 patients who used >15 oxycodone doses experienced a minor postoperative complication.
CONCLUSIONS: Pediatric patients have been overprescribed opioids after operative treatment of supracondylar humerus fractures at our institution. Families who report pain scores >5 of 10 and/or persistent opioid use beyond postoperative day 5 warrant further clinical evaluation. Two of 3 pain outliers in this study experienced a minor postoperative complication. With appropriate parental counseling, satisfactory pain control can likely be achieved with acetaminophen and ibuprofen for most patients. If oxycodone is prescribed for breakthrough pain, then the authors recommend limiting to <6 doses. LEVEL OF EVIDENCE: Level IV-observational, cohort study.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33044375     DOI: 10.1097/BPO.0000000000001639

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

1.  Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study.

Authors:  Samina Ali; Katie Gourlay; Aran Yukseloglu; Rhonda J Rosychuk; Silvia Ortiz; Rick Watts; David W Johnson; Bruce Carleton; Sylvie Le May; Amy L Drendel
Journal:  BMJ Paediatr Open       Date:  2022-05-24

2.  Application Value of Elbow Pressing Method Combined with Zhongtong Ling Application in Children with Swelling and Pain after Operation of Supracondylar Fracture of the Humerus.

Authors:  Liyi Qiu; Youren Wang; Xiaoyu Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-08-23       Impact factor: 3.009

3.  Quantifying unused opioids following emergency and ambulatory care: A systematic review and meta-analysis.

Authors:  Michele P Dyson; Kathryn Dong; William Sevcik; Samir Z Graham; Sabrina Saba; Lisa Hartling; Samina Ali
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-09-30

4.  Subcutaneous Bupivacaine Infiltration Is Not Effective to Support Control of Postoperative Pain in Paediatric Patients Undergoing Spinal Surgery.

Authors:  Anna Danielewicz; Marek Fatyga; Grzegorz Starobrat; Monika Różańska-Boczula; Magdalena Wójciak; Ireneusz Sowa; Sławomir Dresler; Michał Latalski
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.